Yttrium-90 treatment for large liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical study evaluates the efficacy and safety of selective internal radiation therapy (SIRT) using yttrium-90 in patients with unresectable hepatocellular carcinoma (HCC) larger than 7 cm. Participants will receive SIRT after thorough evaluation, and the primary endpoint is the objective response rate (ORR) assessed by modified RECIST criteria. Secondary endpoints include overall survival, progression-free survival, and safety assessments. The study aims to provide insights into the effectiveness of this treatment approach for a challenging patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathologically confirmed or clinically diagnosed HCC
* Unresectable HCC as assessed by a team of surgeons
* The largest tumor size \> 7 cm
* Tumor recurrence after curative treatment (hepatectomy or ablation) is eligible for enrollment
* At least one measurable intrahepatic target lesion
* Appropriate for SIRT treatment after evaluation (including SPECT/CT evaluation after arterial perfusion with 99Tc-MAA)
* Child-Pugh score ≤ 7
* ECOG PS ≤ 1
* Adequate organ and hematologic function with platelet count ≥75×10\^9/L, leukocyte \>3.0×10\^9/L, Neutrophil count ≥1.5×10\^9/L, haemoglobin ≥85 g/L, ALT and AST≤5×ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds
* life expectancy of at least 6 months

Exclusion Criteria:

* Macrovascular invasion or extrahepatic metastasis
* Decompensated liver function, including: ascites, bleeding from gastroesophageal varices, and hepatic encephalopathy
* Organ (heart and kidneys) dysfunction
* History of other malignancies
* Uncontrollable infection
* History of organ or cells transplantation
* History of HIV
* Pregnant or lactating patients

Where it's running

• The Second Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting
• The Second Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Not yet recruiting

Study contacts

• Study coordinator: Mingyue Cai, Dr.
• Email: cai020@yeah.net
• Phone: +86-20-34156205

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Y-90 internal liver radiation followed by tremelimumab and durvalumab for liver cancer with portal vein thrombosis

  This will test whether Y-90 selective internal radiation (SIRT) followed by tremelimumab and durvalumab helps people with non-resectable hepatocellular carcinoma that involves the portal vein.

  Recruiting Phase 2 Center Eugene Marquis · Grenoble and 5 other locations · NCT07122089

• Combining Lenvatinib with SIRT for Advanced Liver Cancer

  This study is testing whether combining a cancer drug called lenvatinib with a type of radiation therapy can help people with advanced liver cancer that hasn't improved with other treatments.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904196

• Combination treatment for large liver cancer with portal vein involvement

  This study is testing a new combination treatment for people with large liver cancer that has spread to the portal vein to see if it works better than the standard treatment.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904183

• Combination therapy for advanced liver cancer patients

  This study is testing a new combination treatment for patients with advanced liver cancer to see if it can improve their chances of survival and how well they tolerate it.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06607107

• Triple therapy for patients with unresectable liver cancer

  This study is testing a new combination treatment for patients with hard-to-treat liver cancer to see if it can help shrink tumors more and improve survival rates.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian and 3 other locations · NCT06561399

• Combining lenvatinib with TACE and HAIC for large liver cancer with portal vein thrombosis

  This study is testing a new combination treatment for people with large liver cancer and blood clots in the portal vein to see if it works better than just one of the treatments alone.

  Recruiting Phase 3 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06492395

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.